-+ 0.00%
-+ 0.00%
-+ 0.00%

Benchmark Maintains Buy on Abbott Laboratories, Lowers Price Target to $120

Benzinga·04/17/2026 12:45:27
Listen to the news
Benchmark analyst Bruce D. Jackson maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $145 to $120.